J.P. Morgan has raised its 2027 revenue estimate for Eli Lilly & Co by 0.7% to $105.67 billion and its adjusted earnings-per-share forecast by 1.1% to $50.99, maintaining an Overweight rating and a December 2026 price target of $1,400. The bank expects total revenue to climb from about $88 billion in 2026 to more than $105 billion in 2027 and $135 billion by 2030, driven largely by Lilly's incretin portfolio, including Zepbound, Mounjaro, and the oral GLP-1 drug Foundayo. J.P. Morgan forecasts combined incretin sales of over $62 billion in 2026, $78 billion in 2027, and more than $100 billion in 2030, implying roughly 20% annualized growth. The bank also sees potential from pipeline candidates retatrutide and eloralintide, while noting risks such as pricing pressure and slower-than-expected rollout of Foundayo.
Eli Lilly and CompanyJ.P. Morgan raised Lilly's 2027 revenue and EPS estimates and maintained Overweight with a $1,400 price target on incretin growth.
JPMorgan Chase & Co